Title Low Prevalence of Pneumocystis pneumonia ( PCP ) but High Prevalence of Pneumocystis dihydropteroate synthase ( dhps ) Gene Mutations in HIV-Infected Persons in Uganda Permalink

Pneumocystis jirovecii pneumonia (PCP) is an important opportunistic infection in patients infected with HIV, but its burden is incompletely characterized in those areas of sub-Saharan Africa where HIV is prevalent. We explored the prevalence of both PCP in HIV-infected adults admitted with pneumonia to a tertiary-care hospital in Uganda and of putative P. jirovecii drug resistance by mutations in fungal dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr). In 129 consecutive patients with sputum smears negative for mycobacteria, 5 (3.9%) were diagnosed with PCP by microscopic examination of Giemsa-stained bronchoalveolar lavage fluid. Concordance was 100% between Giemsa stain and PCR (dhps and dhfr). PCP was more prevalent in patients newly-diagnosed with HIV (11.4%) than in patients with known HIV (1.1%; p = 0.007). Mortality at 2 months after discharge was 29% overall: 28% among PCP-negative patients, and 60% (3 of 5) among PCP-positive patients. In these 5 fungal isolates and an additional 8 from consecutive cases of PCP, all strains harbored mutant dhps haplotypes; all 13 isolates harbored the P57S mutation in dhps, and 3 (23%) also harbored the T55A mutation. No non-synonymous dhfr mutations were detected. PCP is an important cause of pneumonia in patients newlydiagnosed with HIV in Uganda, is associated with high mortality, and putative molecular evidence of drug resistance is prevalent. Given the reliability of field diagnosis in our cohort, future studies in sub-Saharan Africa can investigate the clinical impact of these genotypes. Citation: Taylor SM, Meshnick SR, Worodria W, Andama A, Cattamanchi A, et al. (2012) Low Prevalence of Pneumocystis pneumonia (PCP) but High Prevalence of Pneumocystis dihydropteroate synthase (dhps) Gene Mutations in HIV-Infected Persons in Uganda. PLoS ONE 7(11): e49991. doi:10.1371/journal.pone.0049991 Editor: Ana Paula Arez, Instituto de Higiene e Medicina Tropical, Portugal Received May 15, 2012; Accepted October 19, 2012; Published November 16, 2012 Copyright: 2012 Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported by the National Heart, Lung, and Blood Institute [K24 HL087713 and R01 HL090355 to L.H.] and by the National Institute of Allergy and Infectious Diseases [K23 AI080147 to JLD]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: taylo115@email.unc.edu " Membership of the International HIV-associated Opportunistic Pneumonias (IHOP) Study is provided in the Acknowledgments.

[1]  S. Meshnick,et al.  Low prevalence of Pneumocystis jirovecii lung colonization in Ugandan HIV-infected patients hospitalized with non-Pneumocystis pneumonia. , 2012, Diagnostic microbiology and infectious disease.

[2]  M. Molyneux,et al.  Etiology of suspected pneumonia in adults admitted to a high-dependency unit in Blantyre, Malawi. , 2011, The American journal of tropical medicine and hygiene.

[3]  O. Matos,et al.  Epidemiology and clinical relevance of Pneumocystis jirovecii Frenkel, 1976 dihydropteroate synthase gene mutations. , 2010, Parasite.

[4]  P. Francioli,et al.  Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  P. Hopewell,et al.  Bronchoscopy is useful for diagnosing smear-negative tuberculosis in HIV-infected patients , 2010, European Respiratory Journal.

[6]  A. Cattamanchi,et al.  The Prevalence and Clinical Course of HIV-Associated Pulmonary Cryptococcosis in Uganda , 2010, Journal of acquired immune deficiency syndromes.

[7]  J. Frean,et al.  High Prevalence of Dihydropteroate Synthase Mutations in Pneumocystis jirovecii Isolated from Patients with Pneumocystis Pneumonia in South Africa , 2010, Journal of Clinical Microbiology.

[8]  D. Stark,et al.  Clinical Significance and Phylogenetic Relationship of Novel Australian Pneumocystis jirovecii Genotypes , 2009, Journal of Clinical Microbiology.

[9]  N. H. Duc,et al.  Clinical features and etiology of pneumonia in acid-fast bacillus sputum smear-negative HIV-infected patients hospitalized in Asia and Africa , 2008, AIDS.

[10]  M. Mungthin,et al.  Study of DHPS and DHFR genes of Pneumocystis jirovecii in Thai HIV-infected patients. , 2008, Medical mycology.

[11]  G. Kibiki,et al.  Aetiology and presentation of HIV/AIDS-associated pulmonary infections in patients presenting for bronchoscopy at a referral hospital in northern Tanzania. , 2008, East African medical journal.

[12]  G. Fantoni,et al.  Genotyping of Pneumocystis jiroveci Pneumonia in Italian AIDS Patients: Clinical Outcome Is Influenced by Dihydropteroate Synthase and Not by Internal Transcribed Spacer Genotype , 2007, Journal of acquired immune deficiency syndromes.

[13]  S. Clarke,et al.  Diagnosis and treatment of malaria in peripheral health facilities in Uganda: findings from an area of low transmission in south-western Uganda , 2007, Malaria Journal.

[14]  A. Worku,et al.  Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia , 2007, Scandinavian journal of infectious diseases.

[15]  Marina C Costa,et al.  Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. , 2006, The Journal of antimicrobial chemotherapy.

[16]  H. Zar,et al.  Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. , 2006, Diagnostic microbiology and infectious disease.

[17]  C. Beard,et al.  Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations , 2005, AIDS.

[18]  S. Meshnick,et al.  Mutations in the Pneumocystis jirovecii DHPS Gene Confer Cross-Resistance to Sulfa Drugs , 2005, Antimicrobial Agents and Chemotherapy.

[19]  Jacques Bille,et al.  Mutations of Pneumocystis jirovecii Dihydrofolate Reductase Associated with Failure of Prophylaxis , 2004, Antimicrobial Agents and Chemotherapy.

[20]  S. Meshnick,et al.  Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia , 2004, Emerging infectious diseases.

[21]  H. Zar,et al.  Prevalence of dihydropteroate synthase mutants in HIV-infected South African children with Pneumocystis jiroveci pneumonia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Hauser,et al.  Pneumocystis jiroveci Dihydropteroate Synthase Polymorphisms Confer Resistance to Sulfadoxine and Sulfanilamide in Saccharomyces cerevisiae , 2004, Antimicrobial Agents and Chemotherapy.

[23]  W. Worodria,et al.  Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  J. Kovacs,et al.  Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. , 2002, The Journal of infectious diseases.

[25]  C. Beard,et al.  Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study , 2001, The Lancet.

[26]  C. Beard,et al.  Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. , 2000, The Journal of infectious diseases.

[27]  S. Meshnick,et al.  Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. , 2000, The Journal of infectious diseases.

[28]  J. Kovacs,et al.  Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. , 1999, The Journal of infectious diseases.

[29]  J. Lundgren,et al.  Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia , 1999, The Lancet.

[30]  J. Ioannidis,et al.  A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. , 1996, Archives of internal medicine.

[31]  A. Malin,et al.  Pneumocystis carinii pneumonia in Zimbabwe , 1995, The Lancet.

[32]  J. Bogaerts,et al.  Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda. A fiberoptic bronchoscopic study of 111 cases of undetermined etiology. , 1994, American journal of respiratory and critical care medicine.

[33]  P. Girard,et al.  Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. , 1993, The American review of respiratory disease.

[34]  P. Cregan,et al.  Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens , 1990, Journal of clinical microbiology.

[35]  P. Hopewell,et al.  Evaluation of an indirect fluorescent-antibody stain for detection of Pneumocystis carinii in respiratory specimens , 1990, Journal of clinical microbiology.